Short Communication
Oncogene (2009) 28, 461–468; doi:10.1038/onc.2008.394; published online 3 November 2008
Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab
1Roche Diagnostics GmbH, Pharmaceutical Research Oncology, Penzberg, Germany
Correspondence: Dr CH Ries, Roche Diagnostics GmbH, Pharmaceutical Research Oncology, Nonnenwald 2, D-82377 Penzberg, Germany. E-mail: carola.ries@roche.com
Received 20 March 2008; Revised 10 July 2008; Accepted 1 October 2008; Published online 3 November 2008.
Abstract
Three-dimensional (3D) cell culture techniques are frequently used to model alterations in tissue architecture critically important for tumor development. Here, we report on a detailed comparison of a spheroid model of human epidermal growth factor receptor (HER2) overexpressing cancer cells with the traditional monolayer culture. In 2D culture, HER2 and HER3 form heterodimers, whereas in multicellular spheroids HER2 homodimers are formed. These homodimers localize in membrane rafts, resulting in enhanced inhibition of the proliferation of cancer cells with trastuzumab (Herceptin), a monoclonal antibody specifically targeting HER2. Within the tumor spheroids, HER2 homodimerization leads to enhanced activation of HER2 and results in a switch in signaling pathways from phosphoinositide 3-kinase (PI3K) to mitogen-activated protein kinase (MAPK). Diminished PI3K signaling is accompanied by the activation of the integrin
4/Rac1/PAK 2 signaling cascade. We propose that the described 3D culture system may better reflect some in vivo aspects of HER signaling and can be used to further improve the understanding of the molecular mechanisms of trastuzumab action. Furthermore, the described human multicellular tumor spheroids may allow identification of new targets for the treatment of HER2-positive breast cancer patients who currently benefit suboptimally from trastuzumab treatment.
Keywords:
HER2 signaling, membrane raft, trastuzumab, 3D cell culture
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Somatic pharmacogenomics in cancer
The Pharmacogenomics Journal Review
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
Nature Clinical Practice Oncology Review (01 May 2006)
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
Nature Clinical Practice Oncology Review (01 May 2006)
